Theranexus Société Anonyme (EPA:ALTHX)

France flag France · Delayed Price · Currency is EUR
2.300
+0.020 (0.88%)
Sep 29, 2025, 3:36 PM CET
0.88%
Market Cap19.46M
Revenue (ttm)879.38K
Net Income (ttm)-2.94M
Shares Out8.54M
EPS (ttm)n/a
PE Ration/a
Forward PE5.16
Dividendn/a
Ex-Dividend Daten/a
Volume32,502
Average Volume95,404
Open2.280
Previous Close2.280
Day's Range2.220 - 2.300
52-Week Range0.261 - 3.660
Beta1.93
RSI46.06
Earnings DateSep 25, 2025

About EPA:ALTHX

Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 10
Stock Exchange Euronext Paris
Ticker Symbol ALTHX
Full Company Profile

Financial Performance

In 2024, EPA:ALTHX's revenue was 2.28 million, an increase of 670.55% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.

Financial Statements

News

There is no news available yet.